HHS Launches Tick-Disease Program With Up to $2.5 Million for Alpha-Gal Research

1 articles · Updated · West Virginia Watch · Aug 13

HHS in May announced a multi-million-dollar tick-control pilot, innovation prizes and up to $2.5 million for NIH researchers targeting alpha-gal syndrome as U.S. concern over tick-borne disease rises.
West Virginia illustrates the pressure: Lyme cases quadrupled from about 1,000 in 2020 to 4,000 in 2025 and are on pace to top 4,000 again this year, while 185 alpha-gal cases had been confirmed by late 2025.
Climate change is cited as a key driver, with warmer springs and milder autumns letting deer ticks emerge earlier and feed longer; experts say broad deer culls work mainly on isolated islands, not most mainland areas.
Two West Virginia county health departments now offer doxycycline within 72 hours of a tick bite to prevent Lyme disease, but the antibiotic does not stop alpha-gal syndrome.
A vaccine remains outside the HHS package even as Pfizer said in March it plans to seek approval for the first Lyme vaccine in more than 20 years.

Sources

With Lyme disease cases skyrocketing in West Virginia, could the upcoming Pfizer vaccine completely eradicate this growing ecological threat?

As alpha-gal syndrome turns residents allergic to red meat, how will this bizarre tick-borne illness impact the local agricultural economy?

If warmer seasons are extending tick lifespans, are current repellents enough to protect us from an expanding array of undetected diseases?

1 total